{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:35:05Z","timestamp":1795127705830,"version":"4.10.3"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ygyno.2026.07.018","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:49:50Z","timestamp":1786031390000},"page":"57-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oral anticoagulants reduce venous thromboembolism rates in patients on 1st-line treatment for ovarian Cancer\u2013 A quality improvement project"],"prefix":"10.1016","volume":"212","author":[{"given":"Limor","family":"Helpman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Josephy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Toderis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Tkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Bar-Adon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yfat","family":"Kadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orgad","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Yagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Mor-Hadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Levanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smadar","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Apter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tima","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lubetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Reychav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Korach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.07.018_bb0005","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2026.07.018_bb0010","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy- associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2026.07.018_bb0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.018_bb0020","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low\u2013molecular weight Heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/ajco.12770","article-title":"Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials (RCTs)","volume":"14","author":"Thein","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0045","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0050","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/jth.15235","article-title":"The timing of venous thromboembolism in ovarian cancer patients: a nationwide Danish cohort study","volume":"19","author":"Str\u00f8m Kahr","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/AOG.0000000000001980","article-title":"Incidence and timing of thromboembolic events in patients with ovarian Cancer undergoing neoadjuvant chemotherapy","volume":"129","author":"Greco","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2023.01.012","article-title":"Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: a literature review","volume":"170","author":"Moufarrij","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2023.06.577","article-title":"Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: is it time for thromboprophylaxis?","volume":"176","author":"Shafa","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejogrb.2013.06.004","article-title":"Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival","volume":"170","author":"Abu Saadeh","year":"2013","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0075","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jogc.2021.05.010","article-title":"Venous thromboembolism in patients receiving neoadjuvant chemotherapy for advanced ovarian Cancer and impact on survival","volume":"43","author":"Black","year":"2021","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1377\/hlthaff.21.3.80","article-title":"A user's manual for the IOM'S \u2018quality chasm\u2019 report","volume":"21","author":"Berwick","year":"2002","journal-title":"Health Aff."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0085","unstructured":"Ways to approach the quality improvement process, agency Healthc. Res. Qual. (n.d.), https:\/\/www.ahrq.gov\/cahps\/quality-improvement\/improvement-guide\/4-approach-qi-process\/sect4part2.html."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0090","first-page":"1","article-title":"Quality improvement into practice","volume":"368","author":"Backhouse","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2026.07.018_bb0095","series-title":"What Is Total Quality Control?\u00a0: The Japanese Way, Englewood Cliffs","author":"Ishikawa","year":"1985"},{"key":"10.1016\/j.ygyno.2026.07.018_bb0100","series-title":"The New Economics for Industry","author":"Deming","year":"1993"},{"key":"10.1016\/j.ygyno.2026.07.018_bb0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/bmjqs-2013-001862","article-title":"Systematic review of the application of the plan-do-study-act method to improve quality in healthcare","volume":"23","author":"Taylor","year":"2014","journal-title":"BMJ Qual. Saf."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0110","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.018_bb0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2020.11.020","article-title":"Direct oral anticoagulant use in gynecologic oncology: a Society of Gynecologic Oncology Clinical Practice Statement","volume":"160","author":"Gressel","year":"2021","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:42:19Z","timestamp":1789692139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S0090825826020767"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral anticoagulants reduce venous thromboembolism rates in patients on 1st-line treatment for ovarian Cancer\u2013 A quality improvement project","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}